COMPARATIVE STUDY OF EFFICACY AND SAFETY OF ESCITALOPRAM VERSUS SERTRALINE IN MAJOR DEPRESSIVE DISORDER
Main Article Content
Keywords
Depression, Escitalopram, Sertraline, Hamilton Depression Rating Scale
Abstract
Depression is a commonly occuring mental health disorder affecting all sectors of people worldwide. Mental health is equally emphasised as that of physical health. Depression, an exasperating disorder shows alarming hike in the present and recent past. Selective serotonin reuptake inhibitors are first choice of drugs for depression and frequently prescribed. Still it has not been possible to declare one particular drug to be more efficacious than the other. The purpose of this study is to compare two of the drugs from this class of SSRIs, namely Sertraline and Escitalopram, in terms of efficacy and safety among major depressive disorder patients.
Methodology:
After approval from Institutional Ethical Committee, 120 patients were recruited and randomised into either group A to receive Tab.Escitalopram 10-20mg/day or group B to receive Tab.Sertraline 50-200mg/day.Demographic details and complete history were recorded during enrolment. Clinical examination, screening with Hamilton depression rating scale and lab investigations were done at baseline.
Efficacy was measured by response in terms of improvement of symptoms assessed by scoring with Hamilton Depression Rating Scale at baseline, at 4, 8, and 12 weeks. Safety was ensured by recording vitals of the patients and laboratory parameters at baseline, 4, 8, 12 weeks of study period. Safety was assessed by recording adverse drug reactions reported voluntarily or observed clinically or changes reported in lab investigation during follow up.
Results:
Mean HAM-D score reduction from 20.77 to 8.75 in group A (Escitalopram) and 20.96 at baseline to 8.65 in group B (Sertraline) after 12 weeks therapy was statistically significant within groups. Response rate assessed by reduction of mean HAM-D score did not show statistically significant difference between two groups. The occurrence of adverse effects in sertraline group was higher than escitalopram group and this difference was found to be statistically significant (P=0.007).The study confirms that both Escitalopram and Sertraline are appropriate as first line drugs in treatment for depression. Both drugs showed equal efficacy in producing response and remission. Escitalopram was better tolerated with less number of reported adverse events than sertraline.
References
2. Depressive Disorders. In: Diagnostic and Statistical Manual of Mental Disorders [Internet]. American Psychiatric Association; 2013. (DSM Library). Available from: http://dsm.psychiatryonline.org/doi/abs/10.1176/appi.books.9780890425596.dsm 04
3. Ogle WO, Speisman RB, Ormerod BK. Potential of Treating Age-Related Depression and Cognitive Decline with Nutraceutical Approaches: A Mini-Review. Gerontology. 2013;59(1):23–31.
4. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, et al. Similar Effectiveness of Paroxetine, Fluoxetine, and Sertraline in Primary Care: A Randomized Trial. JAMA. 2001 Dec 19;286(23):2947–55.
5. WHO | Depression [Internet]. WHO. [cited 2017 May 19]. Available from: http://www.who.int/topics/depression/en/
6. Organization WH, others. Depression and other common mental disorders: global health estimates. 2017 [cited 2017 Jul 5]; Available from: http://apps.who.int/iris/bitstream/10665/254610/1/WHO-MSD-MER-2017.2- eng.pdf
7. Reddy MS. Depression: The Disorder and the Burden. Indian J Psychol Med. 2010;32(1):1–2.
8. Chauhan P, Kokiwar PR, Shridevi K, Katkuri S. A study on prevalence and correlates of depression among elderly population of rural South India. Int J Community Med Public Health. 2017 Jan 31;3(1):236–9.
9. Grover S, Dutt A, Avasthi A. An overview of Indian research in depression. Indian J Psychiatry. 2010 Jan 1;52(7):178.
10. A Study on the Prevalence of Depression among Young Adults in South India (PDF Download Available) [Internet]. ResearchGate. [cited 2017 Jul 12]. Available from: https://www.researchgate.net/publication/316989694_A_Study_on_the_Prevalen ce_of_Depression_among_Young_Adults_in_South_India
11. Causes of Depression [Internet]. WebMD. [cited 2017 Jul 4]. Available from: http://www.webmd.com/depression/guide/causes-depression
12. Rigucci S, Serafini G, Pompili M, Kotzalidis GD, Tatarelli R. Anatomical and functional correlates in major depressive disorder: the contribution of neuroimaging studies. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2010 Mar;11(2 Pt 2):165–80.
13. Oakes P, Loukas M, Oskouian RJ, Tubbs RS. The neuroanatomy of depression: A review. Clin Anat. 2017 Jan 1;30(1):44–9.
14. Stahl SM. Stahl’s Essential Psychopharmacology. 4 edition. Cambridge University Press; 2013. 628 p.
15. Lehtinen V, Joukamaa M. Epidemiology of depression: Prevalence, risk factors and treatment situation. Acta Psychiatr Scand. 1994 Feb 1;89:7–10.
16. Saluja G, Iachan R, Scheidt PC, Overpeck MD, Sun W, Giedd JN. Prevalence of and Risk Factors for Depressive Symptoms Among Young Adolescents. Arch Pediatr Adolesc Med. 2004 Aug 1;158(8):760–5.
17. Rajkumar AP, Thangadurai P, Senthilkumar P, Gayathri K, Prince M, Jacob KS. Nature, prevalence and factors associated with depression among the elderly in a rural south Indian community. Int Psychogeriatr. 2009 Apr;21(2):372–8.
18. Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B, et al. Age- and gender- specific prevalence of depression in latest-life – Systematic review and meta- analysis. J Affect Disord. 2012 Feb 1;136(3):212–21.
19. Rechenberg K, Humphries D. Nutritional Interventions in Depression and Perinatal Depression. Yale J Biol Med. 2013 Jun 13;86(2):127–37.
20. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008 Sep;213(1-2):93–118.
21. Gautam S, Jain A, Gautam M, Vahia VN, Grover S. Clinical Practice Guidelines for the management of Depression. Indian J Psychiatry. 2017 Jan;59(Suppl 1):S34–50.
22. Vahia VN. Diagnostic and statistical manual of mental disorders 5: A quick glance. Indian J Psychiatry. 2013;55(3):220–3.
23. Fried EI, Nesse RM. Depression sum-scores don’t add up: why analyzing specific depression symptoms is essential. BMC Med. 2015 Apr 6;13:72.
24. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013 Sep 5;150(2):384–8.
25. Larson SL, Owens PL, Ford D, Eaton W. Depressive Disorder, Dysthymia, and Risk of Stroke: Thirteen-Year Follow-Up From the Baltimore Epidemiologic Catchment Area Study. Stroke. 2001 Sep 1;32(9):1979–83.
26. Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. Jama. 2008;299(20):2391–400.
27. Varela Piñón M, Adán-Manes J. Selective Serotonin Reuptake Inhibitor-Induced Hyponatremia: Clinical Implications and Therapeutic Alternatives. Clin Neuropharmacol. 2017 Aug;40(4):177–9.
28. Yasui-Furukori N, Hashimoto K, Tsuchimine S, Tomita T, Sugawara N, Ishioka M, et al. Characteristics of Escitalopram Discontinuation Syndrome: A Preliminary Study. Clin Neuropharmacol. 2016 Jun;39(3):125–7.
29. Culpepper L. Escitalopram: A New SSRI for the Treatment of Depression in Primary Care. Prim Care Companion J Clin Psychiatry. 2002;4(6):209–14.
30. McCONVILLE BJ, Minnery KL, Sorter MT, West SA, Friedman LM, Christian K. An Open Study of the Effects of Sertraline on Adolescent Major Depression. J Child Adolesc Psychopharmacol. 1996 Jan 1;6(1):41–51.
31. Hindmarch I, Bhatti JZ. Psychopharmacological effects of sertraline in normal, healthy volunteers. Eur J Clin Pharmacol. 1988 Mar 1;35(2):221–3.
32. MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001;7(1):1– 24.
33. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos Biol Fate Chem. 2005 Feb;33(2):262–70.
34. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, et al. Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder: Two Randomized Controlled Trials. JAMA. 2003 Aug 27;290(8):1033–41.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Sankerneni Abhilash
Assistant professor, Department of Pharmacology, Maheshwara Medical College and Hospital
Mrs.k. Ayesha Siddikha
Assistant professor, Department of Anatomy, Maheshwara Medical College and Hospital